Compare iShares Core S&P 500 ETF (IVV) vs Novo Nordisk A/S (NVO) Price & Performance

iShares Core S&P 500 ETFTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Novo Nordisk A/S — how do they compare? iShares Core S&P 500 ETF trades at $751.66, while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S pays a 3.63% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

	IVV	NVO
Sector	Broad Market / Factor	Health
52-Week High	$763.10	$71.70
52-Week Low	$624.65	$35.29
Market Cap	—	$220.53B
Enterprise Value	—	$239.49B
Dividend Yield	—	3.63%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core S&P 500 ETF

No Aura AI signal available yet.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.

Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

IVV

Invesco S&P 500 Equal Weight Consumer Discretionary ETF seen as a Hold, likely underperforming IVV again.Seeking Alpha · 2 days agoNeutral BlackRock's MAXJ ETF offers S&P 500 returns with downside protection but caps gains at 10.6%.24/7 Wall Street · 3 days agoNeutral SPY ETF charges higher fees than its cheaper sibling SPYM with identical S&P 500 exposure.24/7 Wall Street · 4 days agoBearish View details →

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 12 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 16 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.